Processa Pharmaceuticals Secures $5M Funding for Trials

Introduction

Processa Pharmaceuticals Inc. (Nasdaq: PCSA) is a clinical-stage biopharmaceutical company headquartered in Hanover, Maryland. As of June 17, 2025, its share price was $0.6847, representing a 204.18% increase over the previous period, with a trading volume of 27,516,302 shares on the NASDAQ. The company specializes in next-generation chemotherapy (NGC) drugs, which modify existing FDA-approved oncology therapies to potentially improve safety and efficacy.

Corporate Structure and Experience

Founded in October 2017, Processa employs between 11 and 50 staff members. Its leadership team combines regulatory, clinical, and commercialization expertise:

• George Ng, Chief Executive Officer, has overseen multiple drug approvals and FDA submissions across companies including Scilex Pharmaceuticals and Spectrum Pharmaceuticals.
• The board includes Geraldine Pannu (Independent Director), Michael Floyd (BioPharma Entrepreneur), and Russell Skibsted (Executive VP & CFO at Rockwell Medical).
• Patrick Lin, Managing Partner at Primarius Capital, serves as investor relations contact and co-founder.

The collective experience of Processa’s development team includes involvement in over 30 FDA approvals and more than 100 regulatory meetings.

Recent Developments and News

On January 29, 2025, Processa closed a $5.0 million at-the-market public offering under Nasdaq rules, issuing 8,050,672 shares and accompanying warrants at a price of $0.615 to institutional investors and $0.7975 to executive participants. The net proceeds are intended to support ongoing research and operations.

In March 2025, the company announced its participation in the MedInvest Biotech and Pharma Investor Conference, held March 27–28 in New York City, where management delivered a corporate overview. Presentation materials were made available on Processa’s website.

On May 15, 2025, Armistice Capital, LLC filed a Schedule 13G, reporting beneficial ownership of 578,605 shares, which constitutes 9.99% of the company's outstanding shares.

On June 13, 2025, Processa submitted an S-1 registration statement (Accession No. 0001641172-25-014967) under the Securities Act of 1933, indicating plans to offer additional securities and further capitalize its pipeline.

Financial and Strategic Analysis

In its Form 10-K for the year ended December 31, 2024, Processa reported a net loss of $11.9 million, compared to a net loss of $11.1 million in 2023. Research and development expenses increased to $7.3 million (up from $5.8 million in 2023), attributed to clinical trials and regulatory filings. General and administrative costs decreased to $4.8 million (down from $5.7 million in 2023). Cash and cash equivalents totaled $1.2 million at year-end, supplemented by $4.5 million in net proceeds from a public offering in January 2025. Management has indicated that additional capital will be needed to fund operations beyond mid-2025.

Processa’s strategy focuses on acquiring or in-licensing therapies with existing clinical or scientific data, then optimizing trial designs to manage development risks and expedite regulatory reviews. The company plans to out-license assets before or after pivotal studies to facilitate patient access and conserve resources.

Market Position and Industry Context

Processa operates within the oncology biotech sector, focusing on modifying approved drugs rather than de novo drug discovery. Its active pipeline programs include:

• PCS6422 for metastatic colorectal and breast cancer
• PCS499 for ulcerative necrobiosis lipoidica
• PCS12852 for gastroparesis and GI motility disorders

With two candidates in Phase 2 trials and one in pre-clinical development, Processa aims to address high unmet medical needs. The company contends with typical risks associated with biotech firms, including regulatory approval complexities, dependence on third-party manufacturing, ongoing litigation (notably with Elion Oncology), and market competition, while leveraging management's extensive experience in FDA interactions and drug launches.

TL;DR

Processa Pharmaceuticals closed a $5 million public offering on January 29, 2025, and raised an additional $4.5 million in January, extending its cash runway into mid-2025. On June 13, 2025, the company filed an S-1 to register new securities. It reported a net loss of $11.9 million for 2024, influenced by increased R&D expenditures. Its oncology pipeline includes two candidates in Phase 2 trials and one in pre-clinical development, with presentations made at the MedInvest conference in March 2025. As of May 15, 2025, Armistice Capital holds a 9.99% stake in the company. Future funding is deemed necessary to support ongoing trials and regulatory filings.